論文 - 益崎　裕章

Clinically Amyopathic Dermatomyositis Manifested After the Allogeneic Hematopoietic Stem Cell Transplantation: Case Presentation and Literature Review.

Miyagi R, Nakachi S, Tamaki Y, Doi M, Nakajima T, Kitamura S, Tomori S, Hanashiro T, Tamaki K, Morichika K, Nishi Y, Morishima S, Fukushima T, Masuzaki H

Modern rheumatology case reports ( Modern Rheumatology Case Reports )  7 ( 1 ) 102 - 107   2022年08月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

BACKGROUND: Clinically amyopathic dermatomyositis (CADM) lacks muscle symptoms, associating with rapidly progressive interstitial lung disease (RPILD). Anti-melanoma differentiation-associated gene 5 (MDA-5) antibody has been identified as a disease-labeling autoantibody. We report two cases of CADM manifested after the allogeneic hematopoietic stem cell transplantation (allo-HSCT). CASE SERIES: Case 1: A 56-year-old man with acute leukemia received the allo-HSCT. Case 2: A 45-year-old female patient with lymphoma received the allo-HSCT. She received donor lymphocyte infusion (DLI) because of a post-transplant relapse. After allo-HSCT or DLI, Gottron papules emerged, and both patients were diagnosed as CADM based on dermatological findings coupled with the positivity of anti-MDA-5 antibody, accompanied by interstitial shadows consistent with ILD on chest CT. Case 2 was initially diagnosed as a kind of chronic graft versus host disease. Their symptoms were improved by the combination of immunosuppressive agents with a concomitant decrease in anti-MDA-5 antibody levels. For Case 2, Rituximab was subsequently started for relapse of lymphoma, resulting in a substantial decrease in level of anti-MDA-5 antibody and improvement in rash and ILD. CONCLUSION: Our cases raise a possibility that CADM emerges after the HSCT, highlighting the importance of early diagnosis to avoid fated progression into ILD.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed

Detecting Sarcopenia Risk by Diabetes Clustering: A Japanese Prospective Cohort Study.

Tanabe H, Hirai H, Saito H, Tanaka K, Masuzaki H, Kazama JJ, Shimabukuro M

The Journal of clinical endocrinology and metabolism ( The Journal of clinical endocrinology and metabolism )  107 ( 10 ) 2729 - 2736   2022年07月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed CiNii Research

体質医学からみたこれからの先制医療 腸脳連関と生活習慣病

益崎 裕章, Millman Jasmine F., 上間 次己, 根本 雄飛, 岡本 士毅

日本体質医学会雑誌 ( 日本体質医学会 )  84 ( 2 ) 97 - 105   2022年06月

掲載種別: 研究論文（その他学術会議資料等）

Obesity and Voiding Parameters in a Community-Based Population of Okinawa, Japan: Kumejima Digital Health Project (KDHP).

Ashikari A, Miyazato M, Nakamura K, Yamashiro K, Nakamura T, Uema T, Uehara M, Masuzaki H, Saito S, Maeda S, Ishida H, Matsushita M

Metabolites ( Metabolites )  12 ( 5 ) 468 - 468   2022年05月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

(1) Background: Evidence has accumulated regarding the etiology of lower urinary tract symptoms associated with obesity and metabolic syndrome. Therefore, the present study aimed to identify which subjectively and objectively measured voiding parameters were associated with obesity in a community-based population. (2) Methods: Voiding parameters on a self-administered questionnaire and a digital self-health monitoring system for urine excretion (s-HMSU) were compared between participants with and without obesity, defined as a body mass index ≥ 25 kg/m2 (n = 30 and 29, respectively), from a community in Okinawa, Japan. Logistic regression analysis was employed to calculate the odds ratios of abnormalities in voiding parameters for the obese group, with the non-obese group serving as a reference. (3) Results: The obese group had odds ratios of 5.17 (95% confidence interval: 1.33-20.0) for shortened hours of undisturbed sleep (<302 min) by s-HMSU and 7.65 (1.88-31.1) for nighttime urinary frequency by a questionnaire after adjusting for age and sex. In addition, the obese group had an adjusted odds ratio of 2.27 (0.76-6.78) for decreased maximum bladder capacity (<212 mL) by s-HMSU. (4) Conclusion: the results of the present study suggest that nocturia and shortened hours of undisturbed sleep are signs of obesity.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed CiNii Research

Fermented brown rice beverage distinctively modulates the gut microbiota in Okinawans with metabolic syndrome: A randomized controlled trial.

Akamine Y, Millman JF, Uema T, Okamoto S, Yonamine M, Uehara M, Kozuka C, Kaname T, Shimabukuro M, Kinjo K, Mitsuta M, Watanabe H, Masuzaki H

Nutrition research (New York, N.Y.) ( Nutrition Research )  103   68 - 81   2022年04月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

Accumulating evidence to date suggests that brown rice is superior to white rice in regard to its beneficial impact on a number of risk factors of the metabolic syndrome (MetS). However, little is known about the influence of fermented brown rice beverage on the gut microbiota in humans. We therefore hypothesized that its impact would beneficially alter the gut microbiota composition of patients with MetS. Using a 4-week randomized, single-arm study design, subjects (n = 40) were advised to consume a daily fermented brown rice beverage (BA) or fermented white rice beverage (WA) as a replacement of their main meal. Clinical and anthropometric measurements as well as fecal samples were collected at baseline and immediately after completion of the intervention. Gut microbiota was analyzed using 16S ribosomal RNA sequencing and capillary electrophoresis-time-of-flight mass spectrometry was used to measure plasma short-chain fatty acids. Interestingly, ingestion of BA in contrast to WA resulted in a unique elevation in the abundance of number of beneficial species belonging to the Clostridia class, associated with reduced inflammation, and increased short-chain fatty acid production: Lactobacillales bacterium DJF B280 (P = .005), Butyrate producing bacterium A2 207 (P = .012), and Firmicutes bacterium DJF VP44 (P = .038). This study demonstrates that consumption of BA is effective to beneficially modulate the gut microbiota compared with WA in patients with MetS.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed

Elevation of the Plasma Levels of TNF Receptor 2 in Association with Those of CD25, OX40, and IL-10 and HTLV-1 Proviral Load in Acute Adult T-Cell Leukemia.

Kato M, Imaizumi N, Tanaka R, Mizuguchi M, Hayashi M, Miyagi T, Uchihara J, Ohshiro K, Todoroki J, Karube K, Masuzaki H, Tanaka Y, Fukushima T

Viruses ( Viruses )  14 ( 4 ) 751 - 751   2022年04月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

Adult T-cell leukemia/lymphoma (ATL) cells express TNF receptor type-2 (TNFR2) on their surface and shed its soluble form (sTNFR2). We previously reported that sTNFR2 levels were highly elevated in the plasma of patients with acute ATL. To investigate whether its quantitation would be helpful for the diagnosis or prediction of the onset of acute ATL, we examined the plasma levels of sTNFR2 in a large number of specimens obtained from a cohort of ATL patients and asymptomatic human T-cell leukemia virus type 1 (HTLV-1) carriers (ACs) and compared them to those of other candidate ATL biomarkers (sCD25, sOX40, and IL-10) by enzyme-linked immunosorbent assays (ELISA) and HTLV-1 proviral loads. We observed that sTNFR2 levels were significantly elevated in acute ATL patients compared to ACs and patients with other types of ATL (chronic, smoldering, and lymphoma). Importantly, sTNFR2 levels were significantly correlated with those of sCD25, sOX40, and IL-10, as well as proviral loads. Thus, the present study confirmed that an increase in plasma sTNFR2 levels is a biomarker for the diagnosis of acute ATL. Examination of plasma sTNFR2 alone or in combination with other ATL biomarkers may be helpful for the diagnosis of acute ATL.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed

沖縄県、長野県、徳島県の非糖尿病患者におけるインスリンAUCと腹部肥満との連関

比嘉 盛丈, 渡邊 桐子, 澤紙 亜希子, 長谷川 吉正, 佐田 政隆, 益崎 裕章, 島袋 充生

糖尿病 ( (一社)日本糖尿病学会 )  65 ( Suppl.1 ) S - 290   2022年04月 [ 査読有り ]

掲載種別: 研究論文（その他学術会議資料等）

沖縄県、長野県、徳島県の非糖尿病者におけるインスリンAUCと腹部肥満との連関

比嘉 盛丈, 渡邊 桐子, 澤紙 亜希子, 長谷川 吉正, 佐田 政隆, 益崎 裕章, 島袋 充生

日本内分泌学会雑誌 ( (一社)日本内分泌学会 )  98 ( 1 ) 373 - 373   2022年04月 [ 査読有り ]

掲載種別: 研究論文（その他学術会議資料等）

耐糖能異常のリスク上昇に関わる腸内細菌叢組成の探索的解析

上間 次己, 山城 清人, 仲村 武裕, 本間 健一郎, 上原 盛幸, 岡本 士毅, 益崎 裕章

日本内分泌学会雑誌 ( (一社)日本内分泌学会 )  98 ( 1 ) 323 - 323   2022年04月

掲載種別: 研究論文（その他学術会議資料等）

糖尿病患者における循環器疾患の予防と治療を考える 糖尿病クラスター分類から見た循環器疾患の診断と治療

島袋 充生, 田辺 隼人, 齋藤 悠, 益崎 裕章

糖尿病 ( (一社)日本糖尿病学会 )  65 ( Suppl.1 ) S - 39   2022年04月

掲載種別: 研究論文（その他学術会議資料等）

若年発症2型糖尿病の蛋白尿の出現にはHbA1cが時間依存的に関与する

齋藤 悠, 猪狩 翔吾, 佐藤 恵, 佐藤 雅紘, 根本 雄飛, 山口 瑞希, 滝口 善規, 渡邊 桐子, 堀田 悠貴, 田辺 隼人, 岩崎 麻里子, 平井 裕之, 山口 怜, 比嘉 盛丈, 益崎 裕章, 田中 健一, 旭 浩一, 風間 順一郎, 島袋 充生

糖尿病 ( (一社)日本糖尿病学会 )  65 ( Suppl.1 ) S - 269   2022年04月

掲載種別: 研究論文（その他学術会議資料等）

The power of gut-brain interaction as a promising target for healthy longevity

Masuzaki Hiroaki, Uema Tsugumi, Okamoto Shiki

Glycative Stress Research ( 一般社団法人 糖化ストレス研究会 )  9 ( 1 ) 1 - 6   2022年03月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

Hippocrates, the sage of medicine, famously said, "All disease begins in the gut," The gut-brain axis plays an extremely important role in a high-quality strategy for anti-aging throughout the roughly 100-year life span of humans. When the gut-brain axis is functioning properly, it is possible to maintain a healthy body, mind, and cognitive function, while dysfunction in the gut-brain axis can lead to increased risks of a variety of diseases and subsequent deterioration. From this point of view, we call the unlimited power of the gut-brain interaction "gut-brain axis power" and have focused our attention on the molecular medicine of diet and exercise to enhance gut-brain axis power. The degree of gut-brain power varies greatly from person to person, and the power of gut-brain axis is greatly affected by one's lifestyle, including diet, exercise habits, sleep quality, and stress management. Based on this notion, gut brain power is highlighted as a possible factor X to explain individual and constitutional differences in the development and worsening of complications as well as differences in response to diet, exercise, and drug therapy, all of which have occasionally been overlooked in preventive and clinical medicine. The ingested dietary contents are sensed by enteroendocrine cells (EECs) as nutrients, bile acids, or fermentation metabolites of gut microbiota, and are involved in the regulation of secretion of gut-derived peptide hormones, i.e. CCK, GLP-1, PYY, and ghrelin. These gastrointestinal hormones then act on the central nervous system (brain) to exert a considerable influence on the control of appetite and food preference. In addition to sensing by EEC, the various bioactive substances in the gastrointestinal tracts send information to the brain via blood and lymph flow or directly via spinal afferents, and determine all modes of behaviour, including eating habits and physical activity, whether consciously or unconsciously. The ultimate key to the "behaviour modification" that is being discussed in various aspects of society can be said to be gut brain axis power.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  CiNii Research

Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans.

Nakachi S, Okamoto S, Tamaki K, Nomura I, Tomihama M, Nishi Y, Fukushima T, Tanaka Y, Morishima S, Imamura M, Maeda S, Tsutsui M, Matsushita M, Masuzaki H

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie ( Biomedicine and Pharmacotherapy )  149   112864 - 112864   2022年03月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed CiNii Research

【食の謎にせまる】オリーブオイルの謎

Millman Jasmine F., 岡本 士毅, 野村 育美, 上間 次己, 益崎 裕章

消化器病学サイエンス ( (株)先端医学社 )  6 ( 1 ) 38 - 42   2022年03月

掲載種別: 研究論文（その他学術会議資料等）

　概要を見る

地中海食の主要な要素であるエクストラバージンオリーブオイル(Extra Virgin Olive Oil:EVOO)はオレイン酸などの一価不飽和脂肪酸やポリフェノール化合物を高濃度に含有し、心血管病や認知症の予防に寄与することが広く知られている。興味深いことに、EVOOは腸内フローラのバランスや質の改善、消化管免疫機能の向上にも有用であることが明らかになっており、分子メカニズム解明の進展が大きな注目を集めている。本稿ではEVOOの栄養学的特徴、心血管病や認知症の予防効果、腸内環境に与えるインパクトをめぐる最新知見を概観する。(著者抄録)

Psycho-Metabolism-その基礎と臨床-(精神心理代謝連関) 肥満症と精神疾患に共通する病態メカニズム

岡本 士毅, 箕越 靖彦, 益崎 裕章

肥満研究 ( (一社)日本肥満学会 )  27 ( Suppl. ) 169 - 169   2022年03月

掲載種別: 研究論文（その他学術会議資料等）

Specific Expression of KCC2 in the α Cells of Normal and Type 1 Diabetes Model Mouse Pancreatic Islets.

Shimizu-Okabe C, Okada S, Okamoto S, Masuzaki H, Takayama C

Acta histochemica et cytochemica ( 日本組織細胞化学会 )  55 ( 1 ) 47 - 56   2022年02月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

<p>Gamma-aminobutyric acid (GABA) is an inhibitory neurotransmitter in the mature brain; however, it acts excitatory during development. This difference in action depends on the intra­cellular chloride ion concentration, primarily regulated by potassium chloride co-transporter2 (KCC2). Sufficient KCC2 expression results in its inhibitory action. GABA is also abundant in pancreatic islets, where it acts differentially on the islet cells, and is involved in carbohydrate metabolism. However, the mechanisms underlying the differential action remain unknown. We performed immunohistochemistry for glutamic acid decarboxylase (GAD), a synthetic enzyme for GABA, and KCC2 in normal adult islets. GAD was co-localized with insulin in β cells, whereas KCC2 was expressed in glucagon-positive α cells. These results are in line with previous observations that GABA decreases glucagon release but increases insulin release, and suggest that GABA and insulin may work together in reducing blood glucose levels under hyperglycemia. Next, we examined the streptozotocin-induced type1 diabetes mellitus mouse model. GAD and insulin expression levels were markedly decreased. KCC2 was expressed in glucagon-positive cells, whereas insulin- and somatostatin-positive cells were KCC2-negative. These findings suggest that in diabetes model, reduced GABA release may cause disinhibition of glucagon release, resulting in increased blood sugar levels and the maintenance of hyperglycemic state.</p>

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed CiNii Research

Correction to: Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity.

Sasaki A, Yokote K, Naitoh T, Fujikura J, Hayashi K, Hirota Y, Inagaki N, Ishigaki Y, Kasama K, Kikkawa E, Koyama H, Masuzaki H, Miyatsuka T, Nozaki T, Ogawa W, Ohta M, Okazumi S, Shimabukuro M, Shimomura I, Nishizawa H, Saiki A, Seki Y, Shojima N, Tsujino M, Ugi S, Watada H, Yamauchi T, Yamaguchi T, Ueki K, Kadowaki T, Tatsuno I, Joint Committee in the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, the Japan Society for the Study of Obesity.

Diabetology international ( Diabetology International )  13 ( 1 ) 33 - 34   2022年01月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

[This corrects the article DOI: 10.1007/s13340-021-00551-0.].

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed

Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity.

Sasaki A, Yokote K, Naitoh T, Fujikura J, Hayashi K, Hirota Y, Inagaki N, Ishigaki Y, Kasama K, Kikkawa E, Koyama H, Masuzaki H, Miyatsuka T, Nozaki T, Ogawa W, Ohta M, Okazumi S, Shimabukuro M, Shimomura I, Nishizawa H, Saiki A, Seki Y, Shojima N, Tsujino M, Ugi S, Watada H, Yamauchi T, Yamaguchi T, Ueki K, Kadowaki T, Tatsuno I, Joint Committee in the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, the Japan Society for the Study of Obesity.

Diabetology international ( Diabetology International )  13 ( 1 ) 1 - 30   2022年01月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

Bariatric surgery has been shown to have a variety of metabolically beneficial effects for patients with type 2 diabetes (T2D), and is now also called metabolic surgery. At the 2nd Diabetes Surgery Summit held in 2015 in London, the indication for bariatric and metabolic surgery was included in the "algorithm for patients with type T2D". With this background, the Japanese Society for Treatment of Obesity (JSTO), the Japan Diabetes Society (JDS) and the Japan Society for the Study of Obesity (JASSO) have formed a joint committee to develop a consensus statement regarding bariatric and metabolic surgery for the treatment of Japanese patients with T2D. Eventually, the consensus statement was announced at the joint meeting of the 38th Annual Meeting of JSTO and the 41st Annual Meeting of JASSO convened in Toyama on March 21, 2021. In preparing the consensus statement, we used Japanese data as much as possible as scientific evidence to consider the indication criteria, and set two types of recommendation grades, "recommendation" and "consideration", for items for which recommendations are possible. We hope that this statement will be helpful in providing evidence-based high-quality care through bariatric and metabolic surgery for the treatment of obese Japanese patients with T2D. Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-021-00551-0.

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed

Correction to: Metabolic surgery in treatment of obese Japanese patients with type 2 diabetes: a joint consensus statement from the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, and the Japan Society for the Study of Obesity.

Sasaki A, Yokote K, Naitoh T, Fujikura J, Hayashi K, Hirota Y, Inagaki N, Ishigaki Y, Kasama K, Kikkawa E, Koyama H, Masuzaki H, Miyatsuka T, Nozaki T, Ogawa W, Ohta M, Okazumi S, Shimabukuro M, Shimomura I, Nishizawa H, Saiki A, Seki Y, Shojima N, Tsujino M, Ugi S, Watada H, Yamauchi T, Yamaguchi T, Ueki K, Kadowaki T, Tatsuno I, Joint Committee in the Japanese Society for Treatment of Obesity, the Japan Diabetes Society, the Japan Society for the Study of Obesity.

Diabetology international ( Diabetology International )  13 ( 1 ) 31 - 32   2022年01月 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

　概要を見る

[This corrects the article DOI: 10.1007/s13340-021-00551-0.].

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed

Maternal Urinary Cotinine Concentrations During Pregnancy Predict Infant BMI Trajectory After Birth: Analysis of 89617 Mother-Infant Pairs in the Japan Environment and Children's Study.

Hirai H, Okamoto S, Masuzaki H, Murata T, Ogata Y, Sato A, Horiuchi S, Shinohara R, Shinoki K, Nishigori H, Fujimori K, Hosoya M, Yasumura S, Hashimoto K, Yamagata Z, Shimabukuro M, JECS Group.

Frontiers in endocrinology ( Frontiers in Endocrinology )  13   850784 - 13   2022年 [ 査読有り ]

掲載種別: 研究論文（学術雑誌）

• この論文にアクセスする

  DOI
• 関連情報を調べる
  PubMed CiNii Research